Last reviewed · How we verify
NCT05828433
Effect of Epley-Canalith Repositioning Procedure and Vestibular Rehabilitation Therapy in Diabetic Patients With BPPV
NA trial testing Epley-Canalith Repositioning in Benign Paroxysmal Positional Vertigo in 30 participants. Completed in 17 January 2023.
17 January 2023
Quick facts
| Lead sponsor | Dr. Mohammad Abu Shaphe |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 7 January 2022 |
| Primary completion | 17 January 2023 |
| Estimated completion | 17 January 2023 |
| Sites | 1 location across Saudi Arabia |
Drugs / interventions tested
- Epley-Canalith Repositioning
- Vestibular Rehabilitation Therapy
Conditions studied
- Benign Paroxysmal Positional Vertigo — all drugs for Benign Paroxysmal Positional Vertigo →
Sponsor
Dr. Mohammad Abu Shaphe
Who can join
Adults 20 to 70, any sex, with Benign Paroxysmal Positional Vertigo. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Benign paroxysmal positional vertigo (BPPV) is a common inner ear disorder characterized by brief episodes of vertigo caused by changes in head position. The condition can cause significant func-tional impairment and reduced quality of life. BPPV is especially common among diabetic patients. The Epley-Canalith Repositioning Procedure (CRP) and Vestibular Rehabilitation Therapy (VRT) are two commonly used interventions for the treatment of BPPV. The objective of this paper is to determine the effective therapy among Epley-Canalith Repositioning Procedure and Vestibular Rehabilitation for improving balance and posture control in Diabetic patients with Benign Parox-ysmal Positional Vertigo. Thirty subjects with Diabetes Mellitus (Type 2) suffering from Benign Paroxysmal Positional Vertigo (BPPV) were recruited for the study and randomly assigned to groups A and B, underwent Canalith Repositioning Procedure and Vestibular Rehabilitation Therapy respectively. The outcome measures of the study were Vertigo Symptom Scale- Short Form (VSS-sf) score and Berg Balance Scale Form (BBS) score assessed at pre -treatment (pre) and 4 weeks post treatment (post).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness of Epley-Canalith Repositioning Procedure versus Vestibular Rehabilitation Therapy in Diabetic Patients with Posterior Benign Paroxysmal Positional Vertigo: A Randomized Trial.
Shaphe MA, Alshehri MM, Alajam RA, Beg RA, et al · · 2023 · cited 3× · PMID 37240814 · DOI 10.3390/life13051169
Verify or expand the search:
- PubMed search for NCT05828433
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Benign Paroxysmal Positional Vertigo
Currently open trials in the same condition.
- NCT06738823 — Effect of Wii Fit Training in Comparison to Vestibular Rehabilitation Training on Balance in Patients With Benign Paroxy · NA · recruiting
- NCT06725966 — Personalized Treatment of Refractory BPPV · NA · recruiting
- NCT06001047 — Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV · NA · recruiting
- NCT06314581 — Effect of a Multifaceted Educational Intervention on the Implementation of Evidence-based Practices for Benign Paroxysma · active not recruiting
- NCT05834452 — Treatment of Posterior Benign Paroxysmal Positional Vertigo With Mechanical Rotational Chair. · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05828433 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Mohammad Abu Shaphe
- Last refreshed: 25 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05828433.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing